Compare Amylx Pharmaceuticals Inc (AMLX) vs Digital Realty Trust, Inc. (DLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Digital Realty Trust, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Digital Realty Trust, Inc. trades at $179 (market cap $66.75B). The key difference: Digital Realty Trust, Inc. is far larger — about 33.7× Amylx Pharmaceuticals Inc's market cap, and Digital Realty Trust, Inc. pays a 2.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DLR | |
|---|---|---|
Market Cap | $1.98B | $66.75B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $203.91 |
52-Week Low | $7.64 | $147.93 |
Enterprise Value | $1.70B | $84.27B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Digital Realty Trust (DLR) trades at $180.41, up 0.6% on the day, with a bearish technical signal despite strong analyst consensus. The stock shows robust fundamentals with revenue growth to $6.11B in 2025 and net income margin of 21.73%, though valuation ratios like P/E of 47.85 appear elevated. Recent news highlights a $7.8B acquisition of Blackstone's data center stake, expanding its hyperscale portfolio amid AI-driven demand.
Outlook remains positive with a consensus price target of $218.77, implying 21% upside, supported by AI infrastructure expansion. Key risks include high debt levels, execution challenges from recent deals, and interest rate sensitivity. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near support at $178 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →
